Actively Recruiting
Early Exploratory Study of GC012F Injection for Adults with Difficult-to-Treat Generalized Myasthenia Gravis
Led by Daishi Tian · Updated on 2025-09-08
6
Participants Needed
1
Research Sites
29 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting an early exploratory clinical study to examine the safety, tolerability, and initial effectiveness of GC012F Injection in adults with refractory generalized myasthenia gravis GMG. This study also evaluates how the drug moves through and affects the body, along with its immune response. The trial aims to provide early data on this treatment for patients who have not responded well to conventional therapies. The study involves a single group of participants receiving one dose level of CAR-T cells at 3 105 cells per kilogram of body weight. The process includes screening, apheresis collection to obtain cells, lymphodepletion pretreatment, infusion of the GC012F Injection, followed by safety and efficacy monitoring. Dose adjustments may be made based on safety observations. About six participants will be enrolled, and the study allows for backup lower doses if certain safety concerns arise. Participants will be closely monitored for side effects and treatment response for 24 weeks after infusion or until withdrawal. Researchers will assess adverse events, cell behavior in the blood, immune cell changes, muscle weakness scores, quality of life, and antibody levels. Follow-up continues until disease progression, withdrawal, or other endpoints. This comprehensive monitoring helps understand the treatments safety and potential benefits in refractory GMG over time.
CONDITIONS
Brief Title
GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
Research Team
C
Chuan Qin Sub-I
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here